drugset / Trial / NCT04512872
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
RandomizedParallel-groupQuadruple-blindOther
Summary
This study is a Pilot Phase 1, Double-Blind, Randomized, Two-arm, Parallel group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
Timeline
- Start
- 2020-10-20
- Primary completion
- 2021-05-04
- Completion
- 2021-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT-P41 | Unknown | 60 mg | Subcutaneous |
| Comparator | Denosumab | Monoclonal antibody | 60 mg | Subcutaneous |
Indications
No indication recorded.